文献速递认知障碍与痴呆

神经精神症状预测临床前阿尔茨海默病的脑代谢减低

Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer disease.
PubMed 文献 · Neurology · 2017-04-12

研究纳入115名认知正常者,分为临床前AD、无症状风险组和健康对照,用PET和CSF生物标志物分层。基线NPI评分高的临床前AD个体在后扣带皮层等区域FDG摄取增高,且高NPI评分预测2年后后扣带皮层代谢减低,驱动因素为睡眠行为障碍和易激惹。

要点

  • 临床前AD中NPI评分高者基线后扣带皮层FDG摄取增高。
  • 高NPI评分预测临床前AD个体2年后后扣带皮层代谢减低。
  • 睡眠行为障碍和易激惹是驱动代谢异常的主要NPI成分。

核心结论

  • 临床前AD中神经精神症状的严重程度与易受AD病理影响的边缘网络短暂代谢异常相关,并预测后续后扣带皮层代谢减低。

研究设计与样本

  • 研究纳入115名认知正常个体,用[18F]florbetapir PET和CSF磷酸化tau生物标志物分为临床前AD、无症状风险组和健康对照。
  • 采用回归和基于体素的回归模型评估基线NPI与基线及2年FDG PET代谢变化的关系。

主要发现

  • 临床前AD且NPI评分较高的个体基线时后扣带皮层、腹内侧前额叶皮层和右侧前岛叶FDG摄取较高。
  • 仅在临床前AD个体中,高NPI评分预测2年后后扣带皮层代谢减低。
  • 睡眠/夜间行为障碍以及易激惹和情绪不稳是驱动该代谢异常的NPI成分。

临床怎么用

  • 在临床前AD阶段评估NPI评分,尤其关注睡眠行为障碍和易激惹,可能有助于识别后续代谢减低风险个体。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To identify regional brain metabolic dysfunctions associated with neuropsychiatric symptoms (NPS) in preclinical Alzheimer disease (AD). METHODS: We stratified 115 cognitively normal individuals into preclinical AD (both amyloid and tau pathologies present), asymptomatic at risk for AD (either amyloid or tau pathology present), or healthy controls (no amyloid or tau pathology present) using [18F]florbetapir PET and CSF phosphorylated tau biomarkers. Regression and voxel-based regression models evaluated the relationships between baseline NPS measured by the Neuropsychiatric Inventory (NPI) and baseline and 2-year change in metabolism measured by [18F]fluorodeoxyglucose (FDG) PET. RESULTS: Individuals with preclinical AD with higher NPI scores had higher [18F]FDG uptake in the posterior cingulate cortex (PCC), ventromedial prefrontal cortex, and right anterior insula at baseline. High NPI scores predicted subsequent hypometabolism in the PCC over 2 years only in individuals with preclinical AD. Sleep/nighttime behavior disorders and irritability and lability were the components of the NPI that drove this metabolic dysfunction. CONCLUSIONS: The magnitude of NPS in preclinical cases, driven by sleep behavior and irritability domains, is linked to transitory metabolic dysfunctions within limbic networks vulnerable to the AD process and predicts subsequent PCC hypometabolism. These findings support an emerging conceptual framework in which NPS constitute an early clinical manifestation of AD pathophysiology.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Ng KP, Pascoal TA, Mathotaarachchi S, et al. Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer disease. Neurology. 2017. PMID: 28404803. doi:10.1212/WNL.0000000000003916

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。